SCHEMBL6755485

SCHEMBL6755485

[CH]1OCCC1c1ccco1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM5 P08912 10/20 0.43
CHRM3 P20309 10/20 0.43
CHRM2 P08172 9/20 0.43
CHRM4 P08173 9/20 0.43
CHRM1 P11229 9/20 0.43
POLB P06746 4/20 0.39
MAPT P10636 4/20 0.39
KMT2A Q03164 4/20 0.39
TDP1 Q9NUW8 3/20 0.39
NPSR1 Q6W5P4 1/20 0.39
RECQL P46063 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
APOBEC3A P31941 1/20 0.38
APOBEC3G Q9HC16 1/20 0.38
ALDH1A1 P00352 5/20 0.36
KDM4E B2RXH2 3/20 0.36
HPGD P15428 3/20 0.36
GAA P10253 2/20 0.35
MEN1 O00255 2/20 0.35
BLM P54132 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6940138 0.72
SCHEMBL21402172 0.69
SCHEMBL7242954 0.68 TSHR (0.39) KMT2AMEN1HSD17B10TSHR
SCHEMBL9825250 0.66 POLB (0.53) CHRM5CHRM3CHRM2CHRM4CHRM1
SCHEMBL9828621 0.66 CHRM5 (0.47) CHRM5CHRM3CHRM2CHRM4CHRM1
SCHEMBL509970 0.66 POLB (0.44) CHRM5CHRM3CHRM2CHRM4CHRM1
SCHEMBL28726197 0.66
SCHEMBL10472464 0.64 CHRM5 (0.42) CHRM5CHRM3CHRM2CHRM4CHRM1
SCHEMBL5056107 0.64 CHRM5 (0.46) CHRM5CHRM3CHRM2CHRM4CHRM1
SCHEMBL1386940 0.64 POLB (0.52) CHRM5CHRM3CHRM2CHRM4CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040157834-A1 Somatostatin antagonists and agonists that act at the SST subtype 2 receptor PFIZER INC 2004-08-12 US claimed
US-6720330-B2 INCREASING SECRETION OF GROWTH HORMONE, GASTRIN, OR GLUCAGON IN A MAMMAL; INHIBITING THE BINDING OF SOMATOSTATIN TO AN SST2 RECEPTOR PFIZER INC. 2004-04-13 US claimed
US-20020091090-A1 Somatostatin antagonists and agonists COLE BRIDGET M (US) 2002-07-11 US claimed
US-20020091125-A1 Somatostatin antagonists and agonists that act at the SST subtype 2 receptor HAY BRUCE A (US) 2002-07-11 US claimed
US-20040157834-A1 Somatostatin antagonists and agonists that act at the SST subtype 2 receptor PFIZER INC 2004-08-12 US disclosed
US-6720330-B2 INCREASING SECRETION OF GROWTH HORMONE, GASTRIN, OR GLUCAGON IN A MAMMAL; INHIBITING THE BINDING OF SOMATOSTATIN TO AN SST2 RECEPTOR PFIZER INC. 2004-04-13 US disclosed
US-20020091090-A1 Somatostatin antagonists and agonists COLE BRIDGET M (US) 2002-07-11 US disclosed
US-20020091125-A1 Somatostatin antagonists and agonists that act at the SST subtype 2 receptor HAY BRUCE A (US) 2002-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091090-A1 Somatostatin antagonists and agonists GHSR, GHRHR, SSTR3 CHRM5 305/4885CHRM3 315/4885CHRM2 422/4885
US-20040157834-A1 Somatostatin antagonists and agonists that act at the SST subtype 2 receptor SSTR2, GHSR, SSTR1 CHRM5 720/4885CHRM3 442/4885CHRM2 435/4885
US-20020091125-A1 Somatostatin antagonists and agonists that act at the SST subtype 2 receptor SSTR2, GHSR, SSTR1 CHRM5 711/4885CHRM3 401/4885CHRM2 420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.